Shots:

• Bayer signs an option- research and license agreement with Dewpoint's to develop therapies for cardiovascular and gynecological diseases and will contribute up to $100M. Bayer will get an option to exclusively license a specified number of novel therapies developed during research activities
• The collaboration leverages Dewpoint's platform for biomolecular condensates with Bayer's small molecule compound library to develop new therapies. The agreement expands Dewpoint's presence in Germany and promotes its local capabilities to translate the emerging science into therapies
• Dewpoint's drug platform targets biomolecular condensates which provide new insights into cellular functions and expands the traditional drug target space for small molecules by unveiling new targets

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Market Insider